Cardiac regenerative cell therapy is challenged by immune rejection and inadequate cell fate tracking methods. Hence, we knocked down the
B2M gene in an MLC2v-tdTomato reporter hiPSC line through CRISPR-Cas9, resulting in an MHC-I surface deficiency. The edited hiPSCs retained their properties and efficiently differentiated into immature ventricular cardiomyocytes. LDH cytotoxicity assays showed a significant reduction of the CD8+ T-cell-mediated cytotoxicity against
B2M knockout cells. Thus, the generated hiPSC line combines hypoimmunogenic and traceable features.
«
Cardiac regenerative cell therapy is challenged by immune rejection and inadequate cell fate tracking methods. Hence, we knocked down the
B2M gene in an MLC2v-tdTomato reporter hiPSC line through CRISPR-Cas9, resulting in an MHC-I surface deficiency. The edited hiPSCs retained their properties and efficiently differentiated into immature ventricular cardiomyocytes. LDH cytotoxicity assays showed a significant reduction of the CD8+ T-cell-mediated cytotoxicity against
B2M knockout cells. Thus, th...
»